Relationship between a novel polymorphism of the C5L2 gene and coronary artery disease

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Zheng, Ying Ying ^a,b   Xie, Xiang ^a,b   Ma, Yi Tong ^a,b   Yang, Yi Ning ^a,b   Fu, Zhen Yan ^a,b   Li, Xiao Mei ^a,b   Ma, Xiang ^a,b   Chen, Bang Dang ^b   Liu, Fen ^b  

^a XINJIANG MEDICAL UNIVERSITY   (China)

^b Xinjiang Key Laboratory of Cardiovascular Disease Research   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; G PROTEIN COUPLED RECEPTOR; HIGH DENSITY LIPOPROTEIN; LEUCINE; PROLINE; TRIACYLGLYCEROL; CHEMOKINE RECEPTOR; GPR77 PROTEIN, HUMAN; PRIMER DNA;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; C5L2 GENE; CHINA; CHOLESTEROL BLOOD LEVEL; CODON; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; EXON; FEMALE; GENETIC ASSOCIATION; GENETIC MARKER; GENOTYPE; HETEROZYGOTE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; POPULATION DIFFERENTIATION; POPULATION GENETICS; PROTEIN BLOOD LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; ETHNIC GROUP; GENETICS; MIDDLE AGED; NUCLEOTIDE SEQUENCE;

BASE SEQUENCE; CORONARY ARTERY DISEASE; DNA PRIMERS; ETHNIC GROUPS; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, CHEMOKINE;

EID: 79959263956     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020984     Document Type: Article

References (33)

1. Zee RY, Cheng S, Erlich HA, Lindpaintner K, Rifai N, et al. (2006) Genetic variants of arachidonate 5-lipoxygenase-activating protein, and risk of incident myocardial infarction and ischemic stroke: a nested case-control approach. Stroke 37: 2007-2011.
2. Marenberg ME, Risch N, Berkman LF, Floderus B, De Faire U, (1994) Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med 330: 1041-1046.
3. Arsenault BJ, Lemieux I, Després JP, Wareham NJ, Kastelein JJ, et al. (2010) The hypertriglyceridemic-waist phenotype and the risk of coronary artery disease: results from the EPIC-Norfolk prospective population study. CMAJ 182: 1427-32.
4. Raz I, (2010) Relationship between blood glucose control and improved cardiovascular outcome after stent implantation in diabetic patients. Cardiology 116: 48-50.
5. Goswami B, Rajappa M, Singh B, Ray PC, Kumar S, et al. (2010) Inflammation and dyslipidaemia: a possible interplay between established risk factors in North Indian males with coronary artery disease. Cardiovasc J Afr 21: 103-108.
6. Kyriakou T, Pontefract DE, Viturro E, Hodgkinson CP, Laxton RC, et al. (2007) Functional polymorphism in ABCA1 influences age of symptom onset in coronary artery disease patients. Hum Mol Genet 16: 1412-1422.
7. Wan J, Xiong S, Chao S, Xiao J, Ma Y, et al. (2010) PPAR gamma gene C161T substitution alters lipid profile in Chinese patients with coronary artery disease and type 2 diabetes mellitus. Cardiovasc Diabetol 24: 9-13.
8. Iatan I, Dastani Z, Do R, Weissglas-Volkov D, Ruel I, et al. (2009) Genetic variation at the proprotein convertase subtilisin/kexin type 5 gene modulates high-density lipoprotein cholesterol levels. Circ Cardiovasc Genet 2: 467-475.
9. Anuurad E, Yamasaki M, Shachter N, Pearson TA, Berglund L, (2009) ApoE and ApoC-I polymorphisms: association of genotype with cardiovascular disease phenotype in African Americans. J Lipid Res 50: 1472-1478.
10. Cui W, Simaan M, Laporte S, Lodge R, Cianflone K, (2009) C5a- and ASP-mediated C5L2 activation, endocytosis and recycling are lost in S323I-C5L2 mutation. Mol Immunol 46: 3086-98.
11. MacLaren R, Kalant D, Cianflone K, (2007) The ASP receptor C5L2 is regulated by metabolic hormones associated with insulin resistance. Biochem Cell Biol 85: 11-21.
12. Kalant D, Maclaren R, Cui W, Samanta R, Monk PN, et al. (2005) C5L2 is a functional receptor for acylation stimulating protein. J Biol Chem 280: 23936-23944.
13. Cui W, Lapointe M, Gauvreau D, Kalant D, Cianflone K, (2009) Recombinant C3adesArg/acylation stimulating protein (ASP) is highly bioactive: a critical evaluation of C5L2 binding and 3T3-L1 adipocyte activation. Mol Immunol 46: 3207-17.
14. Faraj M, Sniderman AD, Cianflone K, (2004) ASP enhances in situ lipoprotein lipase activity by increasing fatty acid trapping in adipocytes. J Lipid Res 45: 657-66.
15. Xiang SQ, Cianflone K, Kalant D, Sniderman AD, (1999) Differential binding of triglyceride-rich lipoproteins to lipoprotein lipase. J Lipid Res 40: 1655-63.
16. Paglialunga S, Julien P, Tahiri Y, Cadelis F, Bergeron J, et al. (2009) Lipoprotein lipase deficiency is associated with elevated acylation stimulating protein plasma levels. J Lipid Res 50: 1109-19.
17. Saleh J, Al-Khanbashi M, Al-Maarof M, Al-Lawati M, Rizvi SG, et al. (2009) Acylation-stimulating protein increases and correlates with increased progesterone levels during the luteal phase of the menstrual cycle. Eur J Endocrinol 160: 301-7.
18. de Lind van Wijngaarden RF, Cianflone K, Gao Y, Leunissen RW, Hokken-Koelega AC, (2010) Cardiovascular and metabolic risk profile and acylation-stimulating protein levels in children with Prader-Willi syndrome and effects of growth hormone treatment. J Clin Endocrinol Metab 95: 1758-66.
19. Kalant D, Maclaren R, Cui W, Samanta R, Monk PN, et al. (2005) C5L2 is a functional receptor for acylation stimulating protein. J Biol Chem 280: 23936-23944.
20. Cianflone K, Xia Z, Chen LY, (2003) Critical review of acylation stimulating protein physiology in humans and rodents. Biochim Biophys Acta 1609: 127-143.
21. Maslowska M, Wang HW, Cianflone K, (2005) Novel roles for acylation stimulating protein/C3adesArg: a review of recent in vitro and in vivo evidence. Vitam Horm 70: 309-332.
22. Cianflone K, (2003) Acylation stimulating protein and triacylglycerol synthesis: potential drug targets? Curr Pharm Dis 9: 1397-1410.
23. Marcil Michel, Vu Hai, Cui Wei, Dastani Zari, James C, et al. (2006) Identification of a novel C5L2 variant (S323I) in a French-Canadian family with familial combined hyperlipemia. Arterioscler Thromb Vasc Biol 26: 1619-1625.
24. Xie X, Ma YT, Fu ZY, Yang YN, Ma X, et al. (2009) Haplotype Analysis of the CYP8A1 gene associated with myocardial infarction. Clin Appl Thromb-Hem 15: 574-580.
25. Xie X, Ma YT, Fu ZY, Yang YN, Ma X, et al. (2009) Association of polymorphisms of PTGS2 and CYP8A1 with myocardial infarction. Clin Chem Lab Med 47: 347-352.
26. Xie X, Ma Y-T, Yang Y-N, Li X-M, Liu F, et al. (2010) Alcohol Consumption and Ankle-to-Brachial Index: Results from the Cardiovascular Risk Survey. PLoS ONE 5 (12): e15181 doi:10.1371/journal.pone.0015181.
27. Xie X, Ma Y-T, Yang Y-N, Fu Z-Y, Li X-M, et al. (2010) Polymorphisms in the SAA1/2 Gene Are Associated with Carotid Intima Media Thickness in Healthy Han Chinese Subjects: The Cardiovascular Risk Survey. PLoS ONE 5 (11): e13997 doi:10.1371/journal.pone.0013997.
28. Guidelines Subcommittee (1999) World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 17: 151-83.
29. Yang YN, Wang XL, Ma YT, Xie X, Fu ZY, et al. (2010) Association of interaction between smoking and CYP 2C19*3 polymorphism with coronary artery disease in a Uighur population. Clin Appl Thromb Hemost 16: 579-83.
30. Huerta-Vazquez A, Aguilar-Salinas C, Lusis AJ, Cantor RM, Canizales-Quinteros S, et al. (2005) Familial combined hyperlipidemia in Mexicans: association with upstream transcription factor 1 and linkage on chromosome 16q24.1. Arterioscler Thromb Vasc Biol 25: 1985-1991.
31. Aouizerat BE, Allayee H, Cantor RM, Davis RC, Lanning CD, et al. (1999) A genome scan for familial combined hyperlipidemia reveals evidence of linkage with a locus on chromosome 11. Am J Hum Genet 65: 397-412.
32. Ge Genest JJ Jr, Martin-Munley SS, McNamara JR, Ordovas JM, Jenner J, et al. (1992) Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 85: 2025-2033.
33. Claing A, Laporte SA, Caron MG, (2002) Endocytosis of G protein-coupled receptors: roles of G protein-coupled receptor kinases and beta-arrestin proteins. Prog Neurobiol 66: 61-79.